Jeffrey Berinstein, MD
Enriched profileClinical Lecturer, Inflammatory Bowel Disease Program, University of Michigan · University of Michigan
Jeffrey Berinstein is Clinical Lecturer, Inflammatory Bowel Disease Program, University of Michigan at University of Michigan. OpenAlex indexes 177 publications with 1,138 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Jeffrey Aaron Berinstein, MD, is Clinical Lecturer, Inflammatory Bowel Disease Program, University of Michigan. The public record shows 177 publications with 1,138 citations (h-index 15), centered on Inflammatory Bowel Disease, Ocular Diseases and Behçet’s Syndrome, Rheumatoid Arthritis Research and Therapies. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 8 companies, 2 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Inflammatory bowel diseases
- Top research focus: Inflammatory Bowel Disease
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 17.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
Sponsor: Berinstein, Jeffrey
Industry payments
Updated 23 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20256 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Janssen Biotech, Inc.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69%Interleukin-12 Antagonist28.5%Stelara100%Part D≥15 patientsJAK inhibitor13.5%Rinvoq100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
24.5%Aminosalicylate14.4%Mesalamine70%Mesalamine Er30%Part D<11 patientsProton pump inhibitor10%Omeprazole100%Part D≥13 patientsBlood & clotting
6.6%Solutions for parenteral nutrition6.6%Peg 3350-Electrolyte100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Development of Patient-Tailored Adaptive Treatment Strategies for Acute Severe Ulcerative Colitis
University of Michigan at Ann Arbor
FY2026$194,400K23DK134764 - Shifting Acute Severe Ulcerative Colitis Away from the Hospital: A Pilot Randomized Trial of Outpatient ASUC Management
University of Michigan at Ann Arbor
FY2026$117,000R03DK149488 - Development of Patient-Tailored Adaptive Treatment Strategies for Acute Severe Ulcerative Colitis
University of Michigan at Ann Arbor
FY2025$194,400K23DK134764
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression.
Inflammatory bowel diseases
Article2026 - Virtual Multidisciplinary GI Care Clinic Improves Patient Engagement, Satisfaction, and Outcomes at Reduced Costs and Healthcare Utilization: A Prospective Cohort Study.
The American journal of gastroenterology
Article2026 - Feasibility of a Hospital at Home for Management of Acute Severe Ulcerative Colitis: A Retrospective Case Series.
Case reports in gastrointestinal medicine
Case Report2025 - Reddit as a Social Media Self-Management Tool for Inflammatory Bowel Disease: Qualitative Analysis.
Journal of medical Internet research
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeffrey-berinstein-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
med.unc.edu/cgibd/event/gi-epi-conference-getting-smart-about-acute-severe-ulcerative-colitis-developing-personalized-adaptive-treatment-strategies-to-lower-the-colectomy-rate-with-jeffrey-a-berinstein-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.unc.edu ↗ - Other
medresearch.umich.edu/labs-departments/labs/ibd-research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medresearch.umich.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Technion-Israel Institute of Technology (Haifa, Israel)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpgloballearningnetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai